EarningsNubeqa is expected to drive consensus EPS upgrades and improve Orion's ability to raise the dividend, which is of key importance to local investors.

Product PreferenceBayer's Nubeqa sales are driven by a broader prescriber base and doctor preference for Nubeqa over Xtandi/Erleada owing to better tolerability and flexibility for concomitant use with drugs for comorbidities.

Sales GrowthNubeqa's peak sales are lifted to €1.3bn on Bayer's more optimistic outlook, with positive doctor feedback and the IQVIA script trend supporting continued momentum.

Bears Say

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

5.43%

Mutual Funds

― Other Institutional Investors

81.96% Public Companies and

Individual Investors

Detailed Ownership Overview >

1ORNBV FAQ

What was Orion Corporation’s price range in the past 12 months?

Orion Corporation lowest stock price was €37.52 and its highest was €65.70 in the past 12 months.

What is Orion Corporation’s market cap?

Orion Corporation’s market cap is €8.88B.

When is Orion Corporation’s upcoming earnings report date?

Orion Corporation’s upcoming earnings report date is Jul 18, 2025 which is in 29 days.

How were Orion Corporation’s earnings last quarter?

Orion Corporation released its earnings results on Apr 23, 2025. The company reported €0.44 earnings per share for the quarter, beating the consensus estimate of €0.393 by €0.047.

Is Orion Corporation overvalued?

According to Wall Street analysts Orion Corporation’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Orion Corporation pay dividends?

Orion Corporation pays a Annually dividend of €1.629 which represents an annual dividend yield of 2.59%. See more information on Orion Corporation dividends here

What is Orion Corporation’s EPS estimate?

Orion Corporation’s EPS estimate is 0.5.

How many shares outstanding does Orion Corporation have?

Orion Corporation has 108,683,530 shares outstanding.

What happened to Orion Corporation’s price movement after its last earnings report?

Orion Corporation reported an EPS of €0.44 in its last earnings report, beating expectations of €0.393. Following the earnings report the stock price went down -2.374%.

Which hedge fund is a major shareholder of Orion Corporation?

Currently, no hedge funds are holding shares in IT:1ORNBV

Company Description

Orion Corporation

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.